Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
|
|
Adverum Biotechnologies, Inc. (ADVM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/29/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 03/01/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results |
| 08/08/2017 |
8-K
| Quarterly results|
Docs:
|
"Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update MENLO PARK, CA, August 8, 2017 - Adverum Biotechnologies, Inc. , a leading gene therapy company advancing novel medicines that have the potential to address unmet needs in serious rare and ocular diseases, today reported financial results for the second quarter ended June 30, 2017 and provided a corporate update. “We are making important progress with our development and regulatory initiatives to transform Adverum into a clinical-stage company by the end of this year,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies. “Since the beginning of this year, we have held meetings with the FDA, paving the way to advancing our three lead gene therapy programs toward ..." |
|
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 03/06/2017 |
8-K
| Form 8-K - Current report |
| 11/08/2016 |
8-K
| Quarterly results|
Docs:
|
"Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results MENLO PARK, CA, November 8, 2016 - Adverum Biotechnologies, Inc. , a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today reported financial results for the third quarter ended September 30, 2016. “Our new leadership team is focused on executing our plans to advance our three lead gene therapy programs into the clinic to address alpha 1 antitrypsin deficiency, wet AMD and hereditary angioedema,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies. “At recent scientific conferences, we have presented promising preclinical efficacy data on our two new anti-VEGF candidates..." |
|
| 08/09/2016 |
8-K
| Form 8-K - Current report |
| 05/06/2016 |
8-K
| Form 8-K - Current report |
| 03/03/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2015 |
8-K
| Quarterly results |
| 08/13/2015 |
8-K
| Quarterly results|
Docs:
|
"Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program MENLO PARK, Calif., August 13, 2015 - Avalanche Biotechnologies, Inc. , a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported financial results for the second quarter ended June 30, 2015. The company also reported that after further analyses of results from a previously reported Phase 2a trial of AVA-101 for the potential treatment of wet age-related macular degeneration , it will not initiate a Phase 2b clinical trial in the second half of 2015. Instead, Avalanche will conduct additional preclinical studies to investigate optimal dose and delivery of AVA-101 and AVA..." |
|
| 05/13/2015 |
8-K
| Quarterly results|
Docs:
|
"Avalanche Biotechnologies, Inc. Reports First Quarter 2015 Financial Results MENLO PARK, Calif., May 13, 2015 - Avalanche Biotechnologies, Inc. , a clinical-stage biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need, today reported financial results for the first quarter ended March 31, 2015. “The start of 2015 marked important milestones for Avalanche as we continue to advance our pipeline and innovate in next-generation vector technology,” said Thomas W. Chalberg, Jr., Ph.D., founder and chief executive officer. “We're proud to collaborate with the University of Washington and vision scientists Drs. Jay and Maureen Neitz as we develop AVA-322 and AVA-323, our gene therapy product candidates for ..." |
|
| 03/05/2015 |
8-K
| Quarterly results|
Docs:
|
"Avalanche Biotechnologies, Inc. Reports Fourth Quarter and Fiscal 2014 Financial Results MENLO PARK, Calif., March 5, 2015 - Avalanche Biotechnologies, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today reported financial results for the fourth quarter and year ended December 31, 2014. “2014 was an important year marked by many significant milestone achievements, including completing enrollment of our Phase 2a clinical trial of our lead product candidate AVA-101, which we believe could be a transformative therapy for wet AMD patients; embarking on an R&D collaboration with Regeneron; adding key senior management team members to help us execute on our pl..." |
|
| 11/12/2014 |
8-K
| Quarterly results|
Docs:
|
"Avalanche Biotechnologies, Inc. Reports Third Quarter 2014 Financial Results MENLO PARK, Calif., November 12, 2014 - Avalanche Biotechnologies, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today reported financial results and operational highlights for the quarter ended September 30, 2014. “The third quarter of 2014 marked important progress in the history of Avalanche as a leader in the development of gene therapies for diseases of the eye,” said Thomas W. Chalberg, Jr., Ph.D., Chief Executive Officer of Avalanche. “The successful completion of our initial public offering substantially strengthened our balance sheet and provides the financial resources..." |
|
| 09/11/2014 |
8-K
| Quarterly results|
Docs:
|
"Avalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results MENLO PARK, Calif., September 11, 2014 - Avalanche Biotechnologies, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014. “Avalanche has made significant accomplishments, both financially and operationally, in the first half of this year,” said Thomas W. Chalberg, Jr., Ph.D., Chief Executive Officer of Avalanche. “With the successful completion of our recent initial public offering , we have strengthened our balance sheet, which will allow us to advance the clinical development of AVA-101 f..." |
|
|
|